Acrivon Therapeutics Hires Business Development Veteran Levin as CBO
Event summary
- Michaela Levin, Ph.D., appointed Chief Business Officer at Acrivon Therapeutics effective August 31, 2026.
- Levin brings extensive experience in biotechnology business development, including roles at Recursion, Editas Medicine, and Ovid Therapeutics.
- Inducement awards granted include 130,000 stock options and 30,000 restricted stock units, vesting over one year.
- Levin will lead strategic business development and partnering efforts for Acrivon’s AP3 platform and pipeline.
The big picture
Acrivon’s appointment of Michaela Levin as CBO underscores its push to monetize its proprietary AP3 platform through strategic partnerships. Levin’s track record in high-value transactions suggests Acrivon is positioning itself for potential collaborations or acquisitions. The move comes as the company advances its lead programs in oncology, aiming to differentiate itself in a competitive biotech landscape.
What we're watching
- Strategic Partnerships
- How Levin’s industry relationships will accelerate Acrivon’s dealmaking and platform monetization.
- Pipeline Development
- Whether Acrivon can sustain momentum in advancing its lead programs ACR-368 and ACR-2316.
- Execution Risk
- The pace at which Levin can integrate and leverage her transactional experience to maximize the AP3 platform’s value.
Related topics